Genocea to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.


Event: Longwood Healthcare Leaders Winter Webconference – Details
Topic 1: Innovation in Cell Therapy
Format: Panel
Date: Thursday, January 6, 2022
Time: 1:30 PM ET
Topic 2: Making a Big Impact With Limited Resources
Thursday, January 6, 2022
5:10 PM ET


LifeSci Partners 11th Annual Corporate Access Event – Details

Topic 1: Innovative Approaches to Cell Therapy for Oncology
Format: Panel
Date: Friday, January 7, 2022
Time: 8:30 AM ET
Topic 2: Cancer Vaccines: Promises, Promises … Has Their Day Come?
Friday, January 7, 2022
2:00 PM ET

Event: H.C. Wainwright BIOCONNECT Virtual Conference – Details
Topic: Corporate Update
Format: On demand presentation
Date: Monday, January 10, 2022
Time: 7:00 AM ET

Event: Advanced Therapies Week – Details
Topic: Add It Up: 3 Things to Consider for Capacity Expansion
Format: Panel
Date: Wednesday, January 26, 2022
Time: 5:00 PM ET

About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit

Investor Contact:     Media Contact:
Dan Ferry     Sarah O’Connell

error: Content is protected !!